T1	intervention 0 10	Paclitaxel
T2	total-participants 562 565	240
T4	control-participants 673 676	178
T5	eligibility 566 606	patients treated in 6 consecutive trials
T6	intervention-participants 826 828	62
T8	cv-cont-median 1063 1073	148 months
T9	iv-cont-median 1112 1121	45 months
T10	outcome 1156 1198	Estrogen receptor (ER) status was negative
T11	cv-bin-abs 1202 1204	58
T12	cv-bin-percent 1212 1215	33%
T13	iv-bin-abs 1232 1234	40
T14	iv-bin-percent 1242 1245	65%
T15	outcome 1321 1368	objective response rates (complete and partial)
T16	cv-bin-percent 1392 1395	74%
T17	iv-bin-percent 1406 1409	82%
T18	outcome 1416 1444	median overall survival (OS)
T19	outcome 1449 1480	progression-free survival (PFS)
T20	outcome 1631 1640	median OS
T21	cv-cont-median 1651 1660	32 months
T22	iv-cont-median 1671 1680	54 months
T23	outcome 1692 1702	median PFS
T24	cv-cont-median 1713 1722	18 months
T25	iv-cont-median 1733 1742	27 months
T26	total-participants 562 565	240
T3	outcome 1024 1050	median follow-up durations
T7	control 747 796	FAC (5-fluorouracil/doxorubicin/cyclophosphamide)
